On Monday, AbbVie Inc ABBV and Gubra A/S introduced a license settlement to develop GUB014295, a long-acting amylin analog for weight problems. GUB014295 is at the moment in a Part 1 medical trial.
“Our partnership with Gubra marks our entry into the weight problems discipline, providing a compelling alternative primarily based on the potential to deal with affected person wants whereas additionally fostering long-term development for our firm,” stated Robert Michael, CEO of AbbVie.
Additionally Learn: Is Large Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts
A possible long-acting amylin analog, GUB014295 is an agonist that particularly prompts amylin and calcitonin receptors.
Amylin, a satiety hormone, has been recognized as a possible therapeutic goal for weight problems, given its position in activating indicators to the mind that lead to urge for food suppression and the discount of meals consumption whereas additionally appearing as an inhibitory sign to delay gastric emptying.
Underneath the phrases of the settlement, AbbVie will lead the event and commercialization actions of GUB014295 globally.
Gubra will obtain $350 million in complete upfront cost and be eligible to obtain as much as $1.875 billion in improvement, industrial and gross sales milestone funds with tiered royalties on world web gross sales.
William Blair analyst Matt Phipps writes, “We consider this transaction highlights a rising curiosity in amylin agonists (and significantly twin amylin/calcitonin receptor agonists, or DACRAs) as a subsequent wave of weight problems property, significantly for corporations trying to break into the sector regardless of being nicely behind GLP-1 leaders Eli Lilly And Co LLY and Novo Nordisk A/S NVO.”
The analyst highlights a key query is whether or not AbbVie will develop GUB014295 as a standalone remedy, providing a milder weight reduction choice for many who can’t tolerate or don’t reply to GLP-1/GIP agonists.
Alternatively, the corporate might mix it with GLP-1/GIP medicine like Novo Nordisk‘s CagriSema for larger weight reduction. Traders are additionally taken with whether or not AbbVie plans to increase additional within the weight problems market by means of new enterprise offers.
Worth Motion: ABBV inventory is up 0.84% at $210.78 on the final test Monday.
Learn Subsequent:
Picture through Shutterstock.
Market Information and Information dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
